Background: Ivabradine, a specific heart rate lowering agent, was shown in the SHIFT study
to reduce time to first hospitalization for worsening heart failure (HF) in chronic systolic HF …

Aims We explored the effect of treatment with ivabradine, a pure heart rate-slowing agent, on
recurrent hospitalizations for worsening heart failure (HF) in the SHIFT trial. Methods and …

Aims In the SHIFT (Systolic Heart failure treatment with the I f inhibitor ivabradine Trial,
ISRCTN70429960) study, ivabradine reduced cardiovascular death or heart failure (HF) …

Background Hospitalization is an opportunity to optimize heart failure (HF) therapy. As
optimal treatment for hospitalized HF patients in sinus rhythm with heart rate≥ 70 bpm is …

Aims In heart failure (HF) with reduced ejection fraction and sinus rhythm, heart rate
reduction with ivabradine reduces the composite incidence of cardiovascular death and HF …

Background We analysed the effect of ivabradine on outcomes in heart failure (HF) patients
on recommended background therapies with heart rates≥ 75 bpm and< 75 bpm in the …

Background: Ivabradine is recommended in heart failure (HF) patients to reduce
cardiovascular death and hospitalization due to worsening of HF symptoms. Aims and …

Study Design SHIFT is a randomized, double-blind, placebo-controlled, parallel-group trial
including 6,558 patients who had symptomatic heart failure and a left ventricular ejection …

Aims During the post‐discharge phase following a heart failure hospitalization (HFH),
patients are at high risk of early readmission despite standard of care therapy. We examined …

Elevated resting heart rate in chronic heart failure (HF) patients has been associated with
higher mortality and poor prognosis. Ivabradine is a new pure bradycardic agent that has …